<SEC-DOCUMENT>0001179110-17-005387.txt : 20170403
<SEC-HEADER>0001179110-17-005387.hdr.sgml : 20170403
<ACCEPTANCE-DATETIME>20170403163727
ACCESSION NUMBER:		0001179110-17-005387
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170403
FILED AS OF DATE:		20170403
DATE AS OF CHANGE:		20170403

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			McMahon Gerald PhD
		CENTRAL INDEX KEY:			0001290747

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		17734732

	MAIL ADDRESS:	
		STREET 1:		300 ELLIOTT AVENUE WEST
		STREET 2:		SUITE 500
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119-4114
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>edgar.xml
<DESCRIPTION>FORM 4 -
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2017-04-03</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000744218</issuerCik>
        <issuerName>Celldex Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>CLDX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001290747</rptOwnerCik>
            <rptOwnerName>McMahon Gerald PhD</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CELLDEX THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>53  FRONTAGE ROAD, SUITE 220</rptOwnerStreet2>
            <rptOwnerCity>HAMPTON</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08827</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock, par value $.001 per share</value>
            </securityTitle>
            <transactionDate>
                <value>2017-04-03</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>2869</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.61</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>231560</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the &quot;Severance Agreement&quot;) with Celldex Therapeutics, Inc. (&quot;Issuer&quot;) whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share (&quot;Common Stock&quot;) less required tax and other withholdings (the &quot;Withholdings&quot;). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. 66,839 shares of Common Stock, less Withholdings were issued to Reporting Person in March 2017 and the remaining 200,517 shares of Common Stock, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.</footnote>
        <footnote id="F2">Pursuant to the Severance Agreement, on April 3, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person.  This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Avery W. Catlin, attorney-in-fact for Gerald McMahon</signatureName>
        <signatureDate>2017-04-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
